NCT02643082View on ClinicalTrials.gov

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 23, 2015

Primary Completion Date

January 26, 2017

Study Completion Date

January 26, 2017

Conditions
COPD
Interventions
DRUG

GFF MDI (PT003) 14.4/9.6μg

Glycopyrronium and Formoterol Fumarate

DRUG

Placebo MDI

Comparator: Placebo MDI which contains no active ingredients

Trial Locations (1)

2650

Research Site, Edegem

Sponsors
All Listed Sponsors
lead

Pearl Therapeutics, Inc.

INDUSTRY